Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will submit sNDA as soon as possible following study halt because of “superior overall survival efficacy.”
You may also be interested in...
Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.
Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.
Progen Phase III Liver Cancer Trial To Initiate In Second Half Of 2007
Company announces positive Phase II results studying PI-88 in patients who have undergone surgical removal of liver cancer.